Hydrogen Sulphide Treatment Prevents Renal Ischemia-Reperfusion Injury by Inhibiting the Expression of ICAM-1 and NF-kB Concentration in Normotensive and Hypertensive Rats
Open Access
- 19 October 2021
- journal article
- research article
- Published by MDPI AG in Biomolecules
- Vol. 11 (10) , 1549
Abstract
Our main objective was to investigate the effect of chronic administration of hydrogen sulphide donor (sodium hydrosulphide) on the expression of intercellular adhesion molecule-1 (ICAM-1) and concentration of nuclear factor-kappa B (NF-kB) in a renal ischemia-reperfusion injury (IRI) model of WKY and L-nitro-arginine-methyl-ester (L-NAME)-induced hypertensive rats. Sodium hydrosulphide (NaHS) was administered intraperitoneally (i.p.) for 35 days while cystathionine gamma lyase (CSE) inhibitor dL-propargylglycine (PAG) was administered at a single dose of 50 mg/kg. Animals were anesthetised using sodium pentobarbitone (60 mg/kg) and then prepared to induce renal ischemia by clamping the left renal artery for 30 min followed by 3 h of reperfusion. Pre-treatment with NaHS improved the renal functional parameters in both WKY and L-NAME-induced hypertensive rats along with reduction of blood pressure in hypertensive groups. Oxidative stress markers like malondialdehyde (MDA), total superoxide dismutase (T-SOD) and glutathione (GSH) were also improved by NaHS treatment following renal IRI. Levels of ICAM-1 and NF-kB concentration were reduced by chronic treatment with NaHS and increased by PAG administration after renal IRI in plasma and kidney. Treatment with NaHS improved tubular morphology and glomerulus hypertrophy. Pre-treatment with NaHS reduced the degree of renal IRI by potentiating its antioxidant and anti-inflammatory mechanism, as evidenced by decreased NF-kB concentration and downregulation of ICAM-1 expression.Keywords
This publication has 93 references indexed in Scilit:
- Hydrogen sulfide replacement therapy protects the vascular endothelium in hyperglycemia by preserving mitochondrial functionProceedings of the National Academy of Sciences, 2011
- Hydrogen Sulfide Protects against Chemical Hypoxia-Induced Cytotoxicity and Inflammation in HaCaT Cells through Inhibition of ROS/NF-κB/COX-2 PathwayPLOS ONE, 2011
- Amelioration of renal ischaemia–reperfusion injury by liposomal delivery of curcumin to renal tubular epithelial and antigen‐presenting cellsBritish Journal of Pharmacology, 2011
- Production and Actions of Hydrogen Sulfide, a Novel Gaseous Bioactive Substance, in the KidneysThe Journal of Pharmacology and Experimental Therapeutics, 2009
- H 2 S as a Physiologic Vasorelaxant: Hypertension in Mice with Deletion of Cystathionine γ-LyaseScience, 2008
- Hydrogen sulphide and its therapeutic potentialNature Reviews Drug Discovery, 2007
- Regulation of vascular nitric oxide in vitro and in vivo; a new role for endogenous hydrogen sulphide?British Journal of Pharmacology, 2006
- Hydrogen sulfide is an endogenous modulator of leukocyte‐mediated inflammationThe FASEB Journal, 2006
- Pretreatment with EPO reduces the injury and dysfunction caused by ischemia/reperfusion in the mouse kidney in vivoKidney International, 2004
- The vasorelaxant effect of H2S as a novel endogenous gaseous KATP channel openerThe EMBO Journal, 2001